Stockscreener 앱 받기
3.90
0.78%
0.03
시간 외 거래:
3.95
0.05
+1.28%
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Stocks of Atyr Pharma Inc (ATYR) are poised to climb above their peers - SETE News
Recent Insider Activity Suggests Potential Gains for Atyr Pharma Inc (ATYR) - Knox Daily
How to interpret Atyr Pharma Inc (ATYR)’s stock chart patterns - US Post News
aTyr Pharma CFO Broadfoot sells $4,740 in stock - MSN
Atyr Pharma's general counsel Nancy Denyes sells $3,398 in stock - MSN
Trading Day Review: Atyr Pharma Inc (ATYR) Loses Momentum, Closing at 3.57 - The Dwinnex
JPMorgan Chase & Co. Boosts Holdings in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Increases By 25.0% - MarketBeat
Head to Head Contrast: CERo Therapeutics (NASDAQ:CERO) versus Atyr PHARMA (NASDAQ:ATYR) - Defense World
Here's Why We're Watching aTyr Pharma's (NASDAQ:ATYR) Cash Burn Situation - Yahoo Finance
aTyr Pharma to Present Three Posters for Efzofitimod at the - GlobeNewswire
Revolutionary Lung Disease Treatment Shows Promise: Major Updates Coming at ATS 2025 - StockTitan
Cantor Fitzgerald Estimates Atyr PHARMA FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts Atyr PHARMA FY2025 Earnings - MarketBeat
Institutional investors are aTyr Pharma, Inc.'s (NASDAQ:ATYR) biggest bettors and were rewarded after last week's US$29m market cap gain - Simply Wall St
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0% - MarketBeat
Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings - Defense World
Several Insiders Invested In aTyr Pharma Flagging Positive News - Yahoo Finance
aTyr Pharma: Interesting Drug, Difficult Target Market (ATYR) - Seeking Alpha
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Analysts at Cantor Fitzgerald - Defense World
This Toast Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
aTyr Pharma stock soars to 52-week high of $4.16 By Investing.com - Investing.com Canada
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald - MarketBeat
Head-To-Head Analysis: Atyr PHARMA (NASDAQ:ATYR) versus CG Oncology (NASDAQ:CGON) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest - MarketBeat
aTyr Pharma stock soars to 52-week high, hits $3.86 By Investing.com - Investing.com Canada
aTyr Pharma stock soars to 52-week high, hits $3.86 - Investing.com
SEC Form 424B5 filed by aTyr Pharma Inc. - Quantisnow
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
aTyr Pharma, Inc. (NASDAQ:ATYR) is a favorite amongst institutional investors who own 57% - Yahoo Finance
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
aTyr Pharma to Present at JPMorgan Healthcare Conference: Spotlight on Revolutionary tRNA Platform - StockTitan
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook - Investing.com
aTyr Pharma's SWOT analysis: efzofitimod's potential drives stock outlook By Investing.com - Investing.com Canada
aTyr Pharma expands board with new director appointment By Investing.com - Investing.com Canada
ATyr Pharma, Inc. Appoints Eric Benevich to Its Board of Directors - Marketscreener.com
aTyr Pharma expands board with new director appointment - Investing.com India
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors - The Manila Times
aTyr Pharma Strengthens Board with Neurocrine CCO Eric Benevich, Bolsters Commercial Leadership - StockTitan
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
aTyr Pharma Announces Third Positive DSMB Review for - GlobeNewswire
aTyr Pharma's Efzofitimod Phase 3 Trial Clears Critical Safety Review for Pulmonary Sarcoidosis Treatment - StockTitan
Atyr PHARMA (NASDAQ:ATYR) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Survey - Defense World
aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis - The Manila Times
aTyr Pharma to Present Preclinical Research Demonstrating - GlobeNewswire
aTyr Pharma's Novel Fibrosis Treatment Shows Breakthrough Results in Preclinical Studies - StockTitan
Sarcoidosis Market Forecasted to Surge in Coming Years, 2023-2032 Analysis by DelveInsight | Pfizer, United Therapeutics, Xentria, Inc., aTyr Pharma, Inc., Kyorin Pharma, Novartis, Kinevant Sciences - Barchart
1.03%
자본화:
|
볼륨(24시간):